Exelixis Archives -

Exelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after

Exelixis’ Cabometyx misses survival target in liver cancer trial

https://pharmaphorum.com/news/exelixis-cabometyx-misses-survival-target-in-liver-cancer-trial/

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the

Merck gets a leg-up for Keytruda in first-line kidney cancer

https://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/

Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic,

Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC

https://pharmaphorum.com/news/exelixis-takes-20m-option-iconic-zymeworks-cancer-adc/

Bristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy

FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo

https://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug

Exelixis doubles down on ADCs for cancer with NBE, Catalent deals

https://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/

Bristol-Myers Squibb has staked another claim to the first-line kidney cancer market, with impressive new data for the

BMS gets an important win for Opdivo combination in kidney cancer

https://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/

Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a

Exelixis’ Cabometyx approved in second-line liver cancer in US

https://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/

Cabometyx secures new indication in renal cell carcinoma.

Ipsen/Exelixis’ drug approved in EU for kidney cancer

https://pharmaphorum.com/news/ipsenexelixis-drug-approved-eu-kidney-cancer/

Exelixis